NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials
Th company intends to recruit around 100-200 patients who have already participated in previous studies of NX-1207.
In the trial, the company will evaluate the safety of repeat injection of the drug.
Nymox CEO Paul Averback said they are optimistic that the pivotal studies NX02-0017 and NX02-0018 will have full enrollment at a reasonable date.
"The 2 pivotal Phase 3 US studies passed the 500 patient enrollment milestone several months ago,"Averback said.
"We continue to negotiate and have discussions with a number of large marketing partners who have interest in licensing NX-1207 for the US and for Asia."
Nymox and Recordati entered into a development and commercialization licensing agreement of NX-1207 in Europe in December 2010.